RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of “Buy” from Analysts

RxSight, Inc. (NASDAQ:RXSTGet Rating) has been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $19.83.

A number of equities analysts recently commented on RXST shares. Zacks Investment Research upgraded RxSight from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Needham & Company LLC started coverage on RxSight in a research note on Friday, April 8th. They set a “buy” rating and a $18.00 target price for the company.

Several hedge funds and other institutional investors have recently modified their holdings of RXST. Royal Bank of Canada acquired a new stake in shares of RxSight in the third quarter valued at $33,000. New York State Common Retirement Fund acquired a new stake in shares of RxSight in the third quarter valued at $48,000. California State Teachers Retirement System acquired a new stake in shares of RxSight in the third quarter valued at $57,000. American International Group Inc. acquired a new stake in shares of RxSight in the third quarter valued at $58,000. Finally, Deutsche Bank AG acquired a new stake in shares of RxSight in the third quarter valued at $61,000. 29.31% of the stock is owned by institutional investors and hedge funds.

Shares of RxSight stock opened at $12.69 on Monday. RxSight has a one year low of $8.80 and a one year high of $19.67. The company has a current ratio of 15.91, a quick ratio of 15.19 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average is $12.83.

RxSight (NASDAQ:RXSTGet Rating) last announced its quarterly earnings data on Tuesday, March 8th. The company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.02. The company had revenue of $8.43 million for the quarter, compared to analysts’ expectations of $8.40 million. On average, research analysts predict that RxSight will post -3.05 earnings per share for the current year.

RxSight Company Profile (Get Rating)

RxSight, Inc, a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Articles

Analyst Recommendations for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.